RxDoctor Payments Data

Emanuel Dozier, MD

Internal Medicine · Bakersfield, CANPI 1902099708

Payments from drug & device makers

$2,557in general payments, 2019–2025

Across 145 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$506
  • GSK$346
  • Boehringer Ingelheim$207
  • Merck$196
  • Lilly USA, LLC$167
  • Pfizer$154
  • plus $981 from 19 others

What the payments were for

  • Food & beverage$2,53299%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,557 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$33,778
Medicare patients
72
Services billed
467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin80$66,456
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$52,198
EliquisApixaban39$41,086
Combivent RespimatIpratropium/Albuterol Sulfate27$12,294
Breo ElliptaFluticasone/Vilanterol31$11,509
Atrovent HfaIpratropium Bromide20$9,708
OzempicSemaglutide11$9,197
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$8,890
Spiriva RespimatTiotropium Bromide12$5,953
Albuterol Sulfate HfaAlbuterol Sulfate187$5,772
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,087
Potassium Chloride207$2,953
BreynaBudesonide/Formoterol Fumarate13$2,579
Zafirlukast15$2,245
Gabapentin218$2,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat$207$84,703119 claims
GSKTrelegy Ellipta, Breo Ellipta$346$63,707108 claims
PfizerEliquis$154$41,08639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →